Jacobs Levy Equity Management
FHTX icon

Jacobs Levy Equity Management’s Foghorn Therapeutics FHTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.45M Buy
303,757
+34,571
+13% +$190K 0.01% 646
2025
Q4 		$1.45M Buy
269,186
+85,123
+46% +$386K 0.01% 631
2025
Q3 		$900K Sell
184,063
-8,600
-4% -$45.6K ﹤0.01% 738
2025
Q2 		$906K Sell
192,663
-49,153
-20% -$205K ﹤0.01% 773
2025
Q1 		$883K Buy
241,816
+18,036
+8% +$82.2K ﹤0.01% 830
2024
Q4 		$1.06M Buy
223,780
+94,449
+73% +$688K ﹤0.01% 707
2024
Q3 		$1.2M Sell
129,331
-54,973
-30% -$398K ﹤0.01% 692
2024
Q2 		$1.06M Sell
184,304
-31,966
-15% -$190K ﹤0.01% 728
2024
Q1 		$1.45M Buy
216,270
+108,700
+101% +$603K 0.01% 647
2023
Q4 		$694K Buy
107,570
+58,704
+120% +$253K ﹤0.01% 783
2023
Q3 		$244K Sell
48,866
-6,988
-13% -$53.9K ﹤0.01% 899
2023
Q2 		$393K Sell
55,854
-74,993
-57% -$524K ﹤0.01% 851
2023
Q1 		$811K Buy
+130,847
New +$856K 0.01% 738

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Jacobs Levy Equity Management's FHTX Position: Q1 2026 in Review

Jacobs Levy Equity Management increased its Foghorn Therapeutics (FHTX) stake by 13% in Q1 2026, buying an estimated $190K and bringing the position to 303,757 shares worth $1.45M. The position accounts for 0.01% of the portfolio, ranked #646.

Jacobs Levy Equity Management first reported a position in FHTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.45M in Q4 2025. 105 funds tracked by Wall St. Rank hold FHTX as of Q1 2026.

  • Jacobs Levy Equity Management held 303,757 shares of Foghorn Therapeutics worth $1.45M as of Q1 2026.
  • Jacobs Levy Equity Management bought 34,571 Foghorn Therapeutics shares in Q1 2026, an estimated $190K.
  • Foghorn Therapeutics made up 0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #646 holding.
  • Jacobs Levy Equity Management first reported a position in Foghorn Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Jacobs Levy Equity Management's Foghorn Therapeutics position peaked at $1.45M in Q4 2025.
  • 105 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.